Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice

Leo R Fitzpatrick1, Jeffrey S Small1, Wallace H Greene2, Kelly D Karpa1, Sean Farmer3 and David Keller3*

Abstract

Background: Recently, we found that the probiotic strain Bacillus coagulans GBI-30, 6086 (GanedenBC30) improved indices of Clostridium difficile (C. difficile) -induced colitis in mice (Fitzpatrick et al., Gut Pathogens, 2011). Our goal was to determine if BC30 could also prevent the recurrence of C. difficile-induced colitis in mice, following initial treatment with vancomycin. On day 6, the C. difficile strain VPI 10463 was given by oro-gastric gavage at \( \approx 5 \times 10^4 \) CFU to induce colitis. Mice were treated on study days 6 to 10 with vancomycin (50 mg/kg) (vanco) or vehicle (saline) by gavage. On days 10 to 16, mice were dosed by gavage with saline vehicle or BC30 (2 x 10^8 CFU per day). Mice were monitored for mortality, weight loss and diarrhea. On study days 14, 16 and 17, stools and colons were collected for analyzing other parameters of colitis.

Results: The mean stool consistency score in Vehicle/C.difficile/Vanco mice increased from 0.4 (day 10) to a range of 1.1 to 1.4 (days 14 to 17), indicating the recurrence of colitis. On days 13 through 17, the stool consistency scores for the vancomycin/BC30 mice were significantly lower (p< 0.05) than for the vancomycin/vehicle cohort of animals. On day 17, 88.9% of mice treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0004). Colonic myeloperoxidase (Units/2 cm colon) was significantly (p < 0.05) reduced from 4.3 ± 0.7 (Vehicle/C.difficile/Vanco) to 2.6 ± 0.2 (BC30/C. Difficle/Vanco). The colonic histology score and Keratinocyte derived-chemokine level in the colon were also lower in BC30 treated mice.

Summary: In BC30-treated mice, there was evidence of better stool consistency, as well as improved biochemical and histological indices of colitis, following initial treatment of animals with vancomycin.

Conclusion: BC30 limited the recurrence of CD-induced colitis following vancomycin withdrawal in mice.

Keywords: Clostridium difficile, GanedenBC30, Probiotics, Colitis, Mice

Background

Clostridium difficile (C. difficile) infection (CDI) is a very common cause of health-care associated diarrhea and colitis [1]. Moreover, CDI is associated with significant morbidity, as well as increased health care costs [2]. The spectrum of C. difficile associated disease (CDAD) ranges from mild antibiotic associated diarrhea to severe and life threatening pseudomembranous colitis [3]. CDAD is caused by the actions of two toxins (toxin A and toxin B), which are produced by pathogenic strains of C. difficile [4,5]. Toxin A results in the activation of three transcription factors (NF- kB, AP1 and CREB). NF-kB (nuclear factor-kappa B) is involved in chemokine production, and also plays a role in colonocyte apoptosis [6,7]. AP-1 (activator protein-1) plays a role in IL-8 production in response to stimulation of colonocytes with toxin A [8]. CREB (Cyclic-AMP Response Binding Protein) is critical for the production of prostaglandin E2 via inducible cyclooxygenase-2 (COX-2) [9]. This prostaglandin plays an important role in the fluid secretion and diarrhea associated with CDAD.
CDAD is often treated successfully with standard antibiotics such as vancomycin (vanco) or metronidazole [10,11]. However, recurrence occurs in at least 20% of patients [11]. Some clinical studies have focused on combined treatment with vancomycin and probiotics such as *Saccharomyces boulardii* for the treatment of recurrence [12-15]. Therefore, the use of probiotics, for prevention of recurrent disease, may be attractive as part of the overall therapeutic strategy for CDAD [12-15].

*Bacillus coagulans* GBI-30, 6086 (GanedenBC30) is a spore-forming probiotic strain that is resistant to extreme temperatures and survives in the gut environment [16]. BC30 was shown to have anti-inflammatory and immunomodulatory effects *in vitro* and *in vivo* [17,18]. Previously, we reported that BC30 improved various parameters of *C. difficile*-induced colitis in mice [18]. Additionally, BC30 prolonged the survival time in *C. difficile*-infected mice [18]. While the initial research focused on primary treatment of *C. difficile*, this study reached the ability to prevent re-occurrences of *C. difficile* infection following withdrawal of Vancomycin.

Recently, other investigators have described the recurrence of CDAD following vancomycin withdrawal in mice [10,19]. Overall, recurrence is associated with some evidence of disease (weight loss, diarrhea), as well as typical histological evidence of CDAD [10,19]. With knowledge of this previous scientific information, the goal of our study was to determine if BC30 could prevent recurrence of CD-induced colitis following vancomycin withdrawal in mice.

**Results**

**Effects of BC30 on mouse survival and body weight, as well as the presence of *C. difficile* infection and toxins**

Figure 1 shows an overview of the key events associated with the *C. difficile* recurrence model that we used for this study. Cumulative survival rates in the study were: 100% (Vehicle/No *C. difficile*), 87.5% (Vehicle/*C. difficile*/No Vanco), 100% (Vehicle/*C. difficile*/Vanco) and 100% (BC30/*C. difficile*/Vanco). No statistically significant differences were found for mouse survival.

The incidence rates of *C. difficile* infection from study days 14, 16 and 17 were: 0% (0/6, Vehicle/No *C. difficile*), 100% (7/7, Vehicle/*C. difficile*/No Vanco), 97% (28/29, Vehicle/*C. difficile*/Vanco) and 89% (25/28, BC30/*C. difficile*/Vanco) [Figure 2A]. The percentages of toxin A/B positive stools from these study days were: 0% (Vehicle/No *C. difficile*), 57% (Vehicle/*C. difficile*/No Vanco), 41% (Vehicle/*C. difficile*/Vanco) and 64% (BC30/*C. difficile*/Vanco). However, the semi-quantitative determination of toxin A/B levels (n = 6–13 per treatment group) showed increased absorbance readings (1.429 ± 0.456) from the stools of *Vehicle/*C. difficile*/Vanco treated mice, as compared to absorbance readings (1.128 ± 0.410) from stools of BC30/*C. difficile*/Vanco treated animals [Figure 2B].

The mean body weights (grams) of mice on study day 6 were: 20.7 ± 0.5 (Vehicle/No *C. difficile*), 21.7 ± 0.6 (Vehicle/*C. difficile*/No Vanco), 21.8 ± 0.3 (Vehicle/*C. difficile*/Vanco) and 21.9 ± 0.3 (BC30/*C. difficile*/Vanco). Of note, surviving Vehicle/*C. difficile*/No Vanco treated mice did transiently lose an average of 1.1 grams between study days 7 and 9. On study day 17, the mean body weights (grams) of remaining mice (n = 2 to 9 per treatment group) were: 20.5 ± 0.5 (Vehicle/No *C. difficile*), 21.5 ± 0.7 (Vehicle/*C. difficile*/No Vanco), 22.4 ± 0.6 (Vehicle/*C. difficile*/Vanco) and 22.1 ± 0.5 (BC30/*C. difficile*/Vanco). There were no statistically significant differences in net body weight gains during the study (days 6 to 17).

**BC30 treatment significantly improved the stool consistency in *C. difficile* infected mice**

Figure 3 illustrates the effects of BC30 treatment on stool consistencies in *C. difficile* treated mice. The mean stool consistency score in Vehicle/*C. difficile*/Vanco treated mice
The percentages of animals positive for *C. difficile* in the stool were determined by ELISA on study day 14, 16 and 17. * indicates p<0.05 vs. all other *C. difficile* infection groups. B) Toxin A/B levels were determined in a semi-quantitative fashion with an appropriate ELISA kit, as described in the Methods section. The values in the graph represent absorbance readings at 450 nm. * indicates p< 0.05 vs. all other *C. difficile* infection groups.

In Figure 3B, a significant difference (p<0.05) in the percentage of mice with normal stools was evident in the BC30/*C. difficile*/Vanco group, as compared to the Vehicle/*C. difficile*/Vanco group, on days 14 to 17. On day 17, 88.9% of mice treated with BC30 had normal stools compared to 0% of mice with normal stools in the Vehicle treated animals (p=0.0004 vs. Vehicle).

Stool sizes (lengths, with higher numbers indicative or more normal stools) in mm (n = 2 to 18 per group)

---

(red symbols and lines) increased from 0.4 (day 10) to a range of 1.1 to 1.4 for days 14 to 17. This increase in stool consistency score indicates the recurrence of colitis. In contrast, during this time period, there was virtually no increase in the mean stool consistency score of BC30/*C. difficile*/Vanco treated mice (green symbols and lines). The stool consistency scores were significantly lower in this cohort of animals (p < 0.05 vs. Vehicle/*C. difficile*/Vanco treatment) on study days 13 through 17 [Figure 3A].
were: 6.9 ± 0.6 (Vehicle/No C. difficile), 5.7 ± 0.6 (Vehicle/C. difficile/No Vanco), 5.9 ± 0.6 (Vehicle/C. difficile/Vanco) and 7.4 ± 0.4 (BC30/C. difficile/Vanco).

However, there were no statistically significant differences in stool sizes between treatment groups.

BC30 treatment improved biochemical and histological indices of recurrent CDAD in mice

Colonic myeloperoxidase (MPO) was measured with colonic samples from study days 14, 16, and 17. As shown in Figure 4, MPO (Units/2 cm colon) was significantly reduced (p < 0.05) from 4.3 +/-0.7 (Vehicle/C. difficile/Vanco treatment) to 2.6 +/-0.2 (BC30/C. difficile/Vanco treatment).

Representative colonic histology pictures are shown in Figure 5. C. difficile infection, without subsequent Vanco administration, caused altered colonic histopathology. Specifically, some crypt damage as well as modest submucosal edema and moderate influx of inflammatory cells into the lamina propria and sub-mucosa were evident in the colon of this mouse (panel B). In a somewhat similar fashion, Vehicle/C. difficile/Vanco treated mice had clear evidence of histological pathology, including significant sub-mucosal edema (panel C). Overall, BC30 treatment (panel D) resulted in a significant improvement of the

---

**Figure 3 Stool consistency data.**

A) Mice were randomized on study day 6 to one of four treatment groups. All mice in the negative control group (n=6) that did not receive C. difficile (black symbols, lines) generally had normal stools throughout the study. Stool consistency scores were higher in the group of mice (blue symbols, bars) that were treated with Vehicle/C. difficile/No Vanco. In these animals, disease was prominently present on days 7 to 9. For the other two experimental groups, mice received Vehicle/C. difficile/Vanco and either Vehicle (red symbols, lines) to induce disease recurrence (study days 11 to 17), or BC30 at a dose of 2 x 10^9 CFU per day (green symbols, lines). * indicates p < 0.05 vs. BC30/C. difficile/Vanco treatment group on study days 13 through 17.

B) The percentages of mice with normal stools in the Vehicle/C. difficile/Vanco (red symbols, lines) and BC30/C. difficile/Vanco (green symbols/lines) treatment groups is shown in this panel. Data are shown for study days 10 through 17. On days 14 through 17, significant differences (* p < 0.05) were found in the percentages of mice with normal stools in the Vehicle/BC30/Vanco group as compared to the Vehicle/C. difficile/Vanco group. On day 17, 88.9% of mice treated with BC30 had normal stools while this value was 0% with vehicle treatment.

Fitzpatrick et al. Gut Pathogens 2012, 4:13 Page 4 of 9
http://www.gutpathogens.com/content/4/1/13
altered colonic histological pathology, which was observed in the Vehicle/C. difficile cohort of animals (panel C). The mean colonic histology scores were: 3.12 ± 0.35 (Vehicle/No C. difficile), 4.49 ± 0.32 (Vehicle/C. difficile/No Vanco), 5.19 ± 0.15 (Vehicle/C. difficile/Vanco) and 4.29 ± 0.20 (BC30/C. difficile/Vanco). Of note, there was a significant reduction (p < 0.05) in the mean histology score of BC30/C. difficile/Vanco treated mice, as compared to Vehicle/C. difficile/Vanco treated animals (Figure 5E).

The KC (keratinocyte derived chemokine) results (pg/2 cm colon) for all cohorts of mice were: 18.6 ± 1.2 (Vehicle/No C. difficile), 26.1 ± 4.3 (Vehicle/C. difficile/No Vanco), 20.8 ± 2.8 (Vehicle/C. difficile/Vanco) and 18.6 ± 1.9 (BC30/C. difficile/Vanco). Generally, colonic KC levels were higher in both C. difficile/No Vanco and C. difficile/Vanco treated mice. In contrast, the BC30/C. difficile/Vanco treatment group had a colonic KC content that was equivalent to mice that were not infected with C. difficile. However, there were no statistically significant differences between any of the treatment groups.

Some representative colonic COX-2 immunohistochemistry pictures are shown in Figure 6. Interestingly, immunostaining for COX-2 was evident primarily in the colonic epithelial cells from a mouse that was not infected with C. difficile (panel A). In the colon of a Vehicle/C. difficile/Vanco treated animal there was prominent brown COX-2 staining in colonocytes, as well as infiltrating leukocytes within the lamina propria and submucosa (panel B). Of note, only minimal COX-2 immuno-staining (i.e., primarily in surface colonic epithelial cells) was present within the colon of a BC30/C. difficile/Vanco treated mouse (panel C).

Discussion

Other investigators have described the recurrence of CDAD following Vanco withdrawal in mice [10,19]. Chen et al. reported severe recurrent CDAD in mice following the removal of Vanco. CDAD was associated with severe diarrhea, prominent body weight loss, marked histological pathology, and a 58% mortality rate [10]. In contrast, Sun and colleagues found only mild diarrhea, transient body weight loss, and no evidence of mortality following Vanco withdrawal in mice. It should be mentioned that different strains of C. difficile (VPI10463 or UK 101) were used in the two studies, as well as somewhat different Vanco treatment regimens [10,11]. Despite the fact that we used the same strain of C. difficile (VPI10463) as Chen and colleagues, our mortality and stool consistency results (Figure 3) are more similar to those reported by Sun et al. [11]. Differences in these study results may also be related to alterations in endogenous bacterial flora populations within the colonies of mice. Certain types of bacteria that predominate in the colon (e.g., numbers of Firmicutes and Proteobacteria) have recently been shown by other investigators to critically influence the severity of C. difficile induced colitis in mice [20].

Interestingly, our results suggested that treatment of mice with BC30 slightly lowered the overall C. difficile infection rate (Figure 2A), as well as the measured levels of associated toxins in the stool (Figure 2B). However, statistically significant differences were not found compared to the corresponding cohort of vehicle treated animals. These results suggest the possibility that BC30 probiotic treatment may have lowered the actual numbers of C. difficile in the colonic lumen and/or mucosa. However, more detailed follow-up studies would be needed to critically test this possibility.

Previously, we found that pre-treatment of mice with B30 improved the stool consistency during the primary phase of C. difficile infection [18]. In a similar fashion, our results show that BC30 treatment significantly improved both the stool consistency scores and percentage of mice with normal stools (Figure 3) during the recurrence phase (days 11–17) following Vanco withdrawal in mice. Of note, mice treated with BC30 tended to have longer and firmer stools (increased stool size) than Vehicle/C. difficile treated mice. These results re-affirm the positive effects of this probiotic on stool consistency (Figure 3).

Other laboratories have found that toxin A secreted by C. difficile can activate the NF-κB and AP-1 signal transduction system in monocytes and colonic epithelial cells [6,8,21]. This process leads to secretion of a key pro-inflammatory chemokine (IL-8) and subsequent neutrophil influx into the colonic tissue [6,8,21]. Interestingly, BC-30 can significantly inhibit IL-8 directed migration.
of human neutrophils in vitro [17]. Based on these results, we measured the effects of BC30 on colonic MPO, as well the murine chemokine (KC) content in the colons of C. difficile infected mice. Probiotic treatment resulted in a significant reduction in colonic MPO (Figure 4), as well as a diminution in the KC content. However, statistical significance was not achieved for reducing this chemokine, as compared to values in vehicle treated mice. Nevertheless, these positive effects of BC30 on parameters associated with neutrophil influx
into the colon may also contribute to the observed improvement in stool consistency observed in the probiotic-treated mice.

Murine CDAD is associated with a specific colonic histopathology that includes crypt damage, submucosal edema and influx of inflammatory cells [10]. These pathological changes were also evident during the recurrence phase in our Vehicle/C. difficile/Vanco treated mice (panel C, Figure 5). Interestingly, histological pathology also persisted to some degree in the Vehicle/C. difficile/No Vanco cohort of mice (panel B, Figure 5), even at 8 to 11 days after the initial infection with C. difficile. In contrast, mice treated with BC30 showed evidence of improved colonic histopathology, including decreased leukocyte influx into the colon and diminished sub-mucosal edema (panel D, Figure 5). Importantly, the comparisons of mean colonic histology scores showed a statistically significant reduction in B30 treated mice compared to the corresponding vehicle cohort of animals (Figure 5E).

Other investigators have found evidence of in vitro and in vivo COX-2 induction in colonocytes or macrophages following exposure to C. difficile derived toxin A [9,22]. Moreover, inducible COX-2 may contribute through prostaglandin formation to the alteration in stool consistency that is a prominent feature of CDAD [10,18]. Therefore, it is interesting that colonic COX-2 immunostaining was dramatically diminished in the colon of BC30 treated mice (Figure 6). It is possible that this probiotic may affect the CREB-COX-2-PGE2 pathway, which promotes fluid secretion and contributes to CDAD in mice [9,10,18]. Future studies could focus on more critically evaluating the effects of BC30, as well as other Bacillus coagulans probiotic strains, on this important pathway of CDAD.

Conclusions
BC30 limited the recurrence of CD-induced colitis following vancomycin withdrawal in mice. Specifically, this probiotic significantly improved stool consistency of mice in this recurrence model of CDAD. BC30 also significantly attenuated histological and biochemical indices (MPO) of infectious colitis.

Methods
Bacillus coagulans GBI-30, 6086 (GanedenBC30)
BC30 and maltodextrin were obtained from Ganeden Biotech Inc. (Mayfield Heights, OH).

Clostridium difficile (VPI 10463)
VPI 10463 was obtained from Dr. Efi Kokkotu, (Beth Israel Deaconess Medical Center, Boston, MA) and ATCC (Manassas, VA).

Mice
Male C57 Bl/6 mice (= 9 weeks of age) were purchased from Jackson Laboratory (Bar Harbor, ME). Mice were
acclimated in our research facility for approximately 3 to 4 weeks, before use in experimental studies.

**Murine Clostridium difficile-Induced colitis**

The protocol for *Clostridium difficile* recurrence developed by Chen et al. was followed with slight modifications [10]. Briefly, an antibiotic cocktail (kanamycin (0.4 mg/mL), gentamicin (0.035 mg/mL), colistin (850 U/mL), metronidazole (0.215 mg/mL), and vancomycin (0.045 mg/mL)) was given in the drinking water to mice on study days 0 to 3. Subsequently, clindamycin (10 mg/kg) was administered to mice by a single i.p. injection. On study day 6, mice were randomized to receive VPI 10463 (= 5 x 10⁹ CFU) by oro-gastric gavage. A negative disease control group of animals was administered vehicle (0.9% saline). Subsequently, on day 6, mice received either vancomycin (50 mg/kg) or 0.9% saline (vehicle) by oro-gastric gavage, until day 10. On study day 10, animals were randomized to receive either BC30 (2 x 10⁹ CFU per day), or vehicle (50% maltodextrin in 0.9% saline), which were dosed by oro-gastric gavage until study day 16. Both body weight and stool consistency data were collected daily on study days 10 through 17. Stool samples from all mice were scored based on the consistency of the fecal sample, as shown here: 0 = normal, 1 = loose stool, 2 = loose/some diarrhea, 3 = diarrhea, and 4 = severe watery diarrhea [18].

Based on preliminary time course studies, mice were euthanized on days 14, 16, or 17 (i.e., cohorts 1, 2 or 3) in Figure 1. On these study days, we confirmed the presence of *Clostridium difficile* and associated toxins (A and B) in stools with a Wampole™ CD quick check complete kit from TECHLAB (Blacksburg, VA). Furthermore, the amount of toxins A and B in available stool samples was determined in a semi-quantitative fashion by use of a C. DIFFICILE TOX A/B II™ ELISA KIT from TECHLAB (Blacksburg, VA). Also, in some mice, stool size (length in mm) was determined with electronic callipers from available specimens.

On these same study days (days 14, 16 or 17), mice were euthanized; and the distal colon was collected for evaluating morphometric (colon weight), histological and biochemical parameters. An overview of the study design is shown in Figure 1. This study was repeated twice and results were combined in the final data analyses. Since no significant differences in measured parameters of CDAD were found on study days 14, 16, and 17, these data were combined for data analyses. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at the Penn State College of Medicine.

**Colonic histology evaluation**

Using coded slides from the distal colon, four areas from each slide were scored on a three-point severity scale: 0 = Normal, 1 = Mild, 2 = Moderate, 3 = Severe, for three different parameters. These three parameters were epithelial damage, mucosal/submucosal edema and leukocyte infiltration. Therefore, the total score for each slide (i.e., mouse) was between 0 and 9 [18]. Histology photographs (H&E staining) were captured at 200x magnification using an Olympus IMT-2 microscope (Olympus Corporation, Lake Success, NY) and EPIX-XCAP® image capture software (Buffalo Grove, IL).

**Colonic MPO**

Colonic myeloperoxidase (MPO) was utilized as an indicator of neutrophil influx into the mouse colon, as described previously by our laboratory [18]. Results were expressed as Units/2 cm colon.

**Colonic KC (CXCL1) chemokine content**

KC (keratinocyte derived chemokine) is a functionally relevant murine chemokine [7]. The colonic KC content was measured with an ELISA kit from R&D systems (Minneapolis, MN). Results are expressed as pg/2 cm colon.

**COX-2 Immunohistochemistry: Mouse colon**

Generally, we followed the procedures for immunohistochemistry with colonic tissue samples, which have been described previously by our laboratory [23]. For the cyclooxygenase-2 (COX-2) primary antibody, we used a 200-fold dilution, as suggested by the manufacturer (Cell Signaling, Danvers, MA). Representative, COX-2 immunohistochemistry photographs from mouse colons were captured at a 300x magnification, using the aforementioned Olympus IMT-2 microscope and EPIX-XCAP® image capture software program.

**Statistical analyses**

All statistical analyses were performed with a GraphPad Prism® (San Diego, CA). Differences in the percentages of mice with normal stools, as well as percentages of mice with *C. difficile* infection were determined with the Fisher’s exact test. Stool consistency scores were evaluated by the Mann Whitney test. Biochemical and histological data were evaluated using unpaired t test analyses. A p value of < 0.05 was considered to be statistically significant for all parameters.

**Ethical statement**

This study, which utilized mice, was approved by the IACUC at the Penn State College of Medicine. The corresponding author was involved in the intellectual aspects of the study. GanedenBC30 is a patented strain of Ganeden Biotech Inc. All requests to use GanedenBC30 for further research should be made directly to the company and are evaluated on an individual basis.
Abbreviations
BC30: Bacillus coagulans GBI-30, 6086; KC: Keratinocyte derived chemokine; CDAD: Clostridium difficile-associated disease; CDI: Clostridium difficile infection.

Competing interests
None of the authors have any conflict of interest disclosures to make regarding this manuscript, with the exception of Sean Farmer and Dr. David Keller. Sean Farmer and Dr. Keller are paid employee of Ganeden Biotech Inc.

Authors’ contributions
LRF contributed to the technical and intellectual aspects of the manuscript. WHG, KDK, SF. and DK contributed to the intellectual aspects of the paper. JSS contributed to the technical aspect of the manuscript. All the authors read and approved the manuscript.

Acknowledgements
The authors would like to thank Dr. Efi Kokkotou, (Beth Israel Deaconess Medical Center, Boston, MA) for providing VPI 10463 for this study. We would also like to thank Deborah Myers, (Penn State College of Medicine) for providing VPI 10463 for this study. Our research was funded by Ganeden Biotech Inc., Mayfield Heights, OH 44124.

Author details
1Department of Pharmacology, Penn State College of Medicine, 1214 Research Boulevard, Hummelstown, PA 17036, USA. 2Department of Pathology, Penn State College of Medicine, PO Box 850, Hershey, PA 17033, USA. 3Ganeden Biotech Inc., 5800 Landerbrook Drive, Suite 300, Mayfield Heights, OH 44124, USA.

Received: 8 August 2012 Accepted: 12 October 2012 Published: 22 October 2012

References
1. McDonald LC, Kligore GE, Thompson A, Owens RC, Kazavoka SV, Sambol SP, Johnson S, Gerding DN: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433–2441.
2. Pepin J, Valiquetet L, Alary ME, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C: Clostridium-difficile-associated diarrhea in a region of Quebec from 1991–2003: a changing pattern of disease activity. CMAJ 2004, 171:466–472.
3. Johnson S, Gerding DN: Clostridium difficile-associated diarrhea. Clin Infect Dis 1998, 26:1027–1034.
4. Kelly CP, Pothoulakis C, Lamont JT: Clostridium difficile colitis. N Engl J Med 1994, 330:257–262.
5. Pothoulakis C, Lamont JT: Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile infection. Am J Gastroenterol Liver Physiol 2001, 28:G178–G183.
6. Kim JM, Lee JY, Yoon M, Oh YK, Youn J, Kim YJ: NF-κB activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with Clostridium difficile toxin A. Scand J Gastroenterol 2006, 41:453–460.
7. Kim H, Rhee SH, Pothoulakis C, Lamont JT: Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 2007, 133:875–886.
8. Lee JY, Park HR, Oh YK, Kim YJ, Youn J, Han JS, Kim JM: Effects of transcription factor activator protein-1 on interleukin-8 expression and enteralis in response to Clostridium difficile toxin A. J Mol Med 2007, 2007(85):1393–1404.
9. Kim H, Rhee SH, Kokkotou E, Na X, Savidge T, Moyer MP, Pothoulakis C, Lamont JT: Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin-E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J Biol Chem 2005, 280:2317–2324.
10. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Chenkis A, Gerding DN, Kelly CP: A mouse model of clostridium difficile-associated disease. Gastroenterology 2008, 135:1984–1992.
11. Bartlett JG: Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984, 6(Suppl):S235–S241.
12. Surawicz C, McFarland LV, Elmer G, Chinn J: Treatment of recurrent clostridium difficile colitis with vancomycin and saccharomyces boulardii. Am J Gastroenterol 1989, 84:1–5.
13. McFarland LV, Surawicz C, Greenberg RN: A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. JAMA 1994, 271:1913–1918.
14. Surawicz C, McFarland LV, Greenberg RN, Rubin M, Felkey R, Mulligan MF, Garcia RJ, Brandmaker S, Bowen K, Borjaz D, Elmer GW: The search for a better treatment for recurrent clostridium difficile disease: use of high-dose vancomycin combined with saccharomyces boulardii. Clin Infect Dis 2000, 31:1012–1017.
15. Kimme MR, Elmer GW, Surawicz C, McFarland LV: Prevention of further recurrences of clostridium difficile colitis with saccharomyces boulardii. Dig Dis Sci 1990, 35:897–901.
16. Keller D, Farmer S, McCarty A, Gibson G: Bacillus coagulans as a probiotic. Food Sci Technol Bull: Funct Foods 2010, 7:103–109.
17. Jensen GS, Benson RF, Carter SG, Endres JR: Ganeden BC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC Immunol 2010, 11:15.
18. Fitzpatrick LR, Small JS, Greene WH, Karpa KD, Keller D: Bacillus Coagulans GBI-30 (BC30) improves indices of clostridium difficile induced colitis in mice. Gut Pathogens 2011, 3:16.
19. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H: Mouse relapse model of Clostridium difficile infection. Infect Immun 2011, 79:2856–2864.
20. Reeves AE, Theriot CM, Berger IL, Huffnagle GB, Schloss PD, Young VB: The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2011, 2:145–158.
21. Jefferson KK, Smith MF, Bobak DA: Roles of intracellular calcium and NF-κB in the clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J Immunol 1999, 163:5193–5197.
22. Alcantra C, Stenson WJ, Steiner TS, Guerant RL: Role of inducible cyclooxygenase and prostaglandin in Clostridium difficile toxin A-induced secretion and inflammation in an animal model. J Infect Dis 2001, 184:648–652.
23. Fitzpatrick LR, Ludwig D, Hofmann C, Small JS, Groeppe M, Harm S, Lenstra S, Leban J, Ammendola A: 45SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis 2010, 16:1763–1777.

doi:10.1186/1757-4749-4-13
Cite this article as: Fitzpatrick et al.: Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-induced colitis following vancomycin withdrawal in mice. Gut Pathogens 2012 4:13.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit